Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.<\/a><\/h4>\n[\/et_pb_text][et_pb_text admin_label=”Autoren” background_layout=”light” text_orientation=”left” text_font_size=”14″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n
Rizvi NA, Mazi\u00e8res J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf JSouquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.<\/p>\n
[\/et_pb_text][et_pb_text admin_label=”Journal+Ver\u00f6ffentlichung” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]<\/p>\n
Journal: Lancet Oncol
\nVer\u00f6ffentlichung: 16. M\u00e4rz 2015 (Epub 20. Feb. 2015 )<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Journal: Lancet Oncol
\nVer\u00f6ffentlichung: 16. M\u00e4rz 2015 (Epub 20. Feb. 2015 )<\/p>\n","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[40],"project_tag":[],"class_list":["post-1054","project","type-project","status-publish","hentry","project_category-2015-en"],"yoast_head":"\n
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. - Lung Cancer Group Cologne<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. - Lung Cancer Group Cologne\" \/>\n<meta property=\"og:description\" content=\"Journal: Lancet Oncol Ver\u00f6ffentlichung: 16. M\u00e4rz 2015 (Epub 20. Feb. 2015 )\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Lung Cancer Group Cologne\" \/>\n<meta property=\"article:modified_time\" content=\"2016-03-07T14:34:38+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/\",\"url\":\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/\",\"name\":\"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. - Lung Cancer Group Cologne\",\"isPartOf\":{\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/#website\"},\"datePublished\":\"2015-03-16T15:20:31+00:00\",\"dateModified\":\"2016-03-07T14:34:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.lungcancergroup.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects\",\"item\":\"https:\/\/www.lungcancergroup.de\/en\/project\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/#website\",\"url\":\"https:\/\/www.lungcancergroup.de\/en\/\",\"name\":\"Lung Cancer Group Cologne\",\"description\":\"Lungenkrebs Studiengruppe K\u00f6ln\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lungcancergroup.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. - Lung Cancer Group Cologne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/","og_locale":"en_US","og_type":"article","og_title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. - Lung Cancer Group Cologne","og_description":"Journal: Lancet Oncol Ver\u00f6ffentlichung: 16. M\u00e4rz 2015 (Epub 20. Feb. 2015 )","og_url":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/","og_site_name":"Lung Cancer Group Cologne","article_modified_time":"2016-03-07T14:34:38+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/","url":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/","name":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. - Lung Cancer Group Cologne","isPartOf":{"@id":"https:\/\/www.lungcancergroup.de\/en\/#website"},"datePublished":"2015-03-16T15:20:31+00:00","dateModified":"2016-03-07T14:34:38+00:00","breadcrumb":{"@id":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for-patients-with-advanced-refractory-squamous-non-small-cell-lung-cancer-checkmate-063-a-phase-2-single-arm-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.lungcancergroup.de\/en\/"},{"@type":"ListItem","position":2,"name":"Projects","item":"https:\/\/www.lungcancergroup.de\/en\/project\/"},{"@type":"ListItem","position":3,"name":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial."}]},{"@type":"WebSite","@id":"https:\/\/www.lungcancergroup.de\/en\/#website","url":"https:\/\/www.lungcancergroup.de\/en\/","name":"Lung Cancer Group Cologne","description":"Lungenkrebs Studiengruppe K\u00f6ln","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lungcancergroup.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project\/1054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/comments?post=1054"}],"version-history":[{"count":2,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project\/1054\/revisions"}],"predecessor-version":[{"id":1286,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project\/1054\/revisions\/1286"}],"wp:attachment":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/media?parent=1054"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project_category?post=1054"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project_tag?post=1054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}